Analysts expect Merit Medical Systems, Inc. (NASDAQ:MMSI) to announce earnings per share (EPS) of $0.29 for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Merit Medical Systems’ earnings, with estimates ranging from $0.23 to $0.33. Merit Medical Systems posted earnings of $0.28 per share in the same quarter last year, which would suggest a positive year over year growth rate of 3.6%. The business is scheduled to issue its next quarterly earnings report after the market closes on Wednesday, April 25th.
According to Zacks, analysts expect that Merit Medical Systems will report full year earnings of $1.64 per share for the current fiscal year, with EPS estimates ranging from $1.61 to $1.68. For the next financial year, analysts forecast that the business will post earnings of $1.87 per share, with EPS estimates ranging from $1.83 to $1.90. Zacks’ EPS averages are a mean average based on a survey of research analysts that cover Merit Medical Systems.
Merit Medical Systems (NASDAQ:MMSI) last announced its quarterly earnings data on Wednesday, February 28th. The medical instruments supplier reported $0.33 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.32 by $0.01. Merit Medical Systems had a net margin of 3.78% and a return on equity of 9.65%. The firm had revenue of $190.90 million during the quarter, compared to analyst estimates of $187.62 million. During the same quarter in the prior year, the firm posted $0.31 earnings per share. Merit Medical Systems’s quarterly revenue was up 21.0% on a year-over-year basis.
Shares of MMSI traded up $0.35 during mid-day trading on Friday, reaching $45.95. The stock had a trading volume of 278,292 shares, compared to its average volume of 313,289. The company has a current ratio of 2.73, a quick ratio of 1.39 and a debt-to-equity ratio of 0.38. Merit Medical Systems has a 52-week low of $28.75 and a 52-week high of $49.50. The firm has a market capitalization of $2,312.48, a P/E ratio of 35.90, a P/E/G ratio of 2.11 and a beta of 1.29.
Several institutional investors and hedge funds have recently modified their holdings of MMSI. Eagle Asset Management Inc. lifted its position in shares of Merit Medical Systems by 209.5% during the fourth quarter. Eagle Asset Management Inc. now owns 1,874,146 shares of the medical instruments supplier’s stock worth $81,018,000 after purchasing an additional 1,268,635 shares in the last quarter. Carillon Tower Advisers Inc. acquired a new stake in shares of Merit Medical Systems during the fourth quarter worth about $13,788,000. Perceptive Advisors LLC lifted its position in shares of Merit Medical Systems by 774.0% during the fourth quarter. Perceptive Advisors LLC now owns 874,013 shares of the medical instruments supplier’s stock worth $37,757,000 after purchasing an additional 774,013 shares in the last quarter. OppenheimerFunds Inc. lifted its position in shares of Merit Medical Systems by 2,548.7% during the fourth quarter. OppenheimerFunds Inc. now owns 313,866 shares of the medical instruments supplier’s stock worth $13,559,000 after purchasing an additional 302,016 shares in the last quarter. Finally, Neuberger Berman Group LLC lifted its position in shares of Merit Medical Systems by 1,420.2% during the third quarter. Neuberger Berman Group LLC now owns 304,049 shares of the medical instruments supplier’s stock worth $12,876,000 after purchasing an additional 284,049 shares in the last quarter. 95.22% of the stock is currently owned by institutional investors and hedge funds.
About Merit Medical Systems
Merit Medical Systems, Inc designs, develops, manufactures, and markets various disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. The company operates through Cardiovascular and Endoscopy segments. It provides various peripheral intervention products, including access, angiography, intervention, and drainage and biopsy products to alleviate patients suffering from peripheral vascular and non-vascular diseases; and cardiac intervention products to aid in the treatment of various cardiac conditions specific to interventional cardiology and electrophysiology, including cardiac rhythm management and lead management.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Merit Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merit Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.